|
Intelectol® Consumer Profile |
|
|
 |
Elderly
The most obvious one, the elderly, as they have "severe" problems. However, this is not necessarily the most effective user as cognitive deterioration is normally more advanced. Clinical trials on over 30,000 patients have shown that Vinpocetine enhances memory in people suffering from cognitive deterioration. |
 |
Middle-Age
Our principal customers are "baby boomers", active and starting to suffer from symptoms of memory loss. They enjoy high economic standards . They turn to a health care professional when suffering from slight problems and are probably inclined to buy something new to enhance their memory capacity. |
 |
Young
Young people who want to enhance their memory, such as students. They are a promising consumer but would probably not go to the health care professional because of memory loss as they do not have yet this problem. Nevertheless they will ask health consultants at their health food stores to suggest something to aid their memory as they approach examinations. |
 |
Clinical trials
On hundreds of healthy volunteers have shown that Vinpocetine improves memory capacity, especially in young and middle aged people (25 to 45 years old).
Clinical trials on about 30,000 patients show that Vinpocetine stimulates memory in people with cognitive impairment. |
These statements have not been evaluated by the Food and Drug Administration (FDA).
This product is not intended to diagnose, treat, cure, or prevent any disease.
|
|
